Featured Research

from universities, journals, and other organizations

Nervous system disease: A new outlet for an old drug?

Date:
August 15, 2013
Source:
BioMed Central Limited
Summary:
A sixty-year old drug designed to treat vitamin B1 deficiency helps ease the symptoms of a chronic, progress nervous system disease, a clinical trial reveals. A large-scale, randomized controlled trial is now needed to help reveal the drugs true potential.

A sixty-year old drug designed to treat vitamin B1 deficiency helps ease the symptoms of a chronic, progress nervous system disease, a clinical trial published in the open access journal BMC Medicine reveals. A large-scale, randomised controlled trial is now needed to help reveal the drugs true potential.

The disease goes by the lengthy moniker of human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis or 'HAM/TSP' for short. It's developed by a subset of people infected with the sexually-transmitted retrovirus HTLV-1, which infects up to 20 million people worldwide, mainly in equatorial regions. The result is a chronic, progressive demyelinating disease of the lower extremities, leading to muscle weakness, spasms, paraplegia and urinary problems.

Twenty-four HAM/TSP patients, who had had the disease for up to 50 years, took the drug -- prosultiamine -- daily as part of the open-label study. Twelve weeks later, most of the patients were more mobile -- they walked more quickly and were faster at going down stairs. Bladder capacity increased and bladder problems lessened, Tatsufumi Nakamura and colleagues report.

The condition is currently managed with drugs that alter the immune response, such as corticosteroids and interferon-alpha. But their efficacy is contested, and they manage symptoms rather than cure the disease. Prosultiamine, on the other hand, reduced levels of the HTLV-1 provirus in the patients' blood, a sign that the drug may be altering the underlying pathology rather than just managing symptoms.

Results from an earlier trial suggested the drug may prove useful therapeutically, but treatment lasted just 2 weeks. Here, the drug produced favourable results with no serious adverse side effects after 3 months of treatment.

Prosultiamine is already used in the clinic to treat a couple of brain disorders induced by vitamin B1 deficiency. Studies have shown it to be safe and stable. The data presented here suggest that prosultiamine could be a promising therapeutic tool for HAM/TSP, so the next step is larger, randomised, blinded clinical trials to assess its therapeutic value.

A commentary by Jun-Ichi Kira will be published at the same time in BMC Medicine.


Story Source:

The above story is based on materials provided by BioMed Central Limited. Note: Materials may be edited for content and length.


Journal References:

  1. Tatsufumi Nakamura, Tomohiro Matsuo, Taku Fukuda, Shinji Yamato, Kentaro Yamaguchi, Ikuo Kinoshita, Toshio Matsuzaki, Yoshihiro Nishiura, Kunihiko Nagasato, Tomoko Narita-Masuda, Hideki Nakamura, Katsuya Satoh, Hitoshi Sasaki, Hideki Sakai, Atsushi Kawakami. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Medicine, 2013; 11 (1): 182 DOI: 10.1186/1741-7015-11-182
  2. Jun-Ichi Kira. Therapeutic benefits of an oral vitamin B1 derivative for HAM/TSP. BMC Medicine, 2013; 11 (1): 183 DOI: 10.1186/1741-7015-11-183

Cite This Page:

BioMed Central Limited. "Nervous system disease: A new outlet for an old drug?." ScienceDaily. ScienceDaily, 15 August 2013. <www.sciencedaily.com/releases/2013/08/130815084757.htm>.
BioMed Central Limited. (2013, August 15). Nervous system disease: A new outlet for an old drug?. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2013/08/130815084757.htm
BioMed Central Limited. "Nervous system disease: A new outlet for an old drug?." ScienceDaily. www.sciencedaily.com/releases/2013/08/130815084757.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins